Associated Papers
Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945.
Wang Y et al.
Npj Precision Oncology, 2025
De Novo EGFR -ALK and EGFR -ROS1 Co-Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis.
Shen L et al.
Cancer Medicine, 2025
D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer.
Shi Y et al.
Briefings in Bioinformatics, 2024
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
Wu L et al.
Annals of Translational Medicine, 2022
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A et al.
International Journal of Molecular Sciences, 2019
Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.
Lo Russo G et al.
Oncotarget, 2017
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
Yan XE et al.
Oncotarget, 2017
Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.
Li Y et al.
Molecular and Clinical Oncology, 2017
Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.
Vu HA et al.
Asia-pacific Journal of Clinical Oncology, 2016
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Sweis RF et al.
Cureus, 2016
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Structural Stability and Flexibility Direct the Selection of Activating Mutations in Epidermal Growth Factor Receptor Kinase.
Paladino A et al.
Journal of Chemical Information and Modeling, 2015
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.
Karachaliou N et al.
Expert Review of Respiratory Medicine, 2015
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK et al.
Lung Cancer (amsterdam, Netherlands), 2012
Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer.
Pennycuick A et al.
International Journal of Clinical Practice, 2012
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The energy landscape analysis of cancer mutations in protein kinases.
Dixit A et al.
Plos One, 2011
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Williams MD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2010
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Sakurada A et al.
Clinical Lung Cancer, 2006
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005